Naomi Beck1,2, Fieke Hoeijmakers1,2, Erwin M Wiegman3, Hans J M Smit4, Franz M Schramel5, Willem H Steup6, Ad F T M Verhagen7, Wilhelmina H Schreurs8, Michel W J M Wouters1,9. 1. Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands. 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Radiation Oncology, Isala, Zwolle, The Netherlands. 4. Department of Pulmonology, Rijnstate Hospital, Arnhem, The Netherlands. 5. Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands. 6. Department of Surgery, HAGA Hospital, Den Haag, The Netherlands. 7. Department of Cardiothoracic Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands. 8. Department of Surgery, North-West Clinics, Alkmaar, The Netherlands. 9. Department of Surgical oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Quality registries play an important role in the professional quality system for cancer treatment in The Netherlands. This article provides insight into the Dutch Lung Cancer Audit (DLCA); its core principles, initiation and development, first results and what lessons can be learned from the Dutch experience. METHODS: Cornerstones of the DLCA are discussed in detail, including: audit aims; the leading role for clinicians; web-based registration and feedback; data handling; multidisciplinary evaluation of quality indicators; close collaborations with all stakeholders in healthcare and transparency of results. RESULTS: In 2012 the first Dutch lung cancer specific sub-registry, focusing on surgical treatment was started. Since 2016 all major treating specialisms (lung oncologists, radiation-oncologists, general- and cardiothoracic surgeons-represented in the DLCA-L, -R and -S sub-registries respectively) have joined. Over time, the number of participating hospitals and included patients has increased. In 2016, the numbers of included patients with a non-small cell lung cancer (NSCLC) were 3,502 (DLCA-L), 2,427 (DLCA-R) and 1,979 (DLCA-S). Between sub-registries mean age varied from 66 to 70 years, occurrence of Eastern Cooperative Oncology Group (ECOG) performance score 2+ varied from 3.3% to 20.8% and occurrence of clinical stage I-II from 27.6% to 81.3%. Of all patients receiving chemoradiotherapy 64.2% was delivered concurrently. Of the surgical procedures 71.2% was started with a minimally invasive technique, with a conversion rate of 18.7%. In 2016 there were 17 publicly available quality indicators-consisting of structure, process and outcome indicators- calculated from the DLCA. CONCLUSIONS: the DLCA is a unique registry to evaluate the quality of multidisciplinary lung cancer care. It is accepted and implemented on a nationwide level, enabling participating healthcare providers to get insight in their performance, and providing other stakeholders with a transparent evaluation of this performance, all aiming for continuous healthcare improvement.
BACKGROUND: Quality registries play an important role in the professional quality system for cancer treatment in The Netherlands. This article provides insight into the Dutch Lung Cancer Audit (DLCA); its core principles, initiation and development, first results and what lessons can be learned from the Dutch experience. METHODS: Cornerstones of the DLCA are discussed in detail, including: audit aims; the leading role for clinicians; web-based registration and feedback; data handling; multidisciplinary evaluation of quality indicators; close collaborations with all stakeholders in healthcare and transparency of results. RESULTS: In 2012 the first Dutch lung cancer specific sub-registry, focusing on surgical treatment was started. Since 2016 all major treating specialisms (lung oncologists, radiation-oncologists, general- and cardiothoracic surgeons-represented in the DLCA-L, -R and -S sub-registries respectively) have joined. Over time, the number of participating hospitals and included patients has increased. In 2016, the numbers of included patients with a non-small cell lung cancer (NSCLC) were 3,502 (DLCA-L), 2,427 (DLCA-R) and 1,979 (DLCA-S). Between sub-registries mean age varied from 66 to 70 years, occurrence of Eastern Cooperative Oncology Group (ECOG) performance score 2+ varied from 3.3% to 20.8% and occurrence of clinical stage I-II from 27.6% to 81.3%. Of all patients receiving chemoradiotherapy 64.2% was delivered concurrently. Of the surgical procedures 71.2% was started with a minimally invasive technique, with a conversion rate of 18.7%. In 2016 there were 17 publicly available quality indicators-consisting of structure, process and outcome indicators- calculated from the DLCA. CONCLUSIONS: the DLCA is a unique registry to evaluate the quality of multidisciplinary lung cancer care. It is accepted and implemented on a nationwide level, enabling participating healthcare providers to get insight in their performance, and providing other stakeholders with a transparent evaluation of this performance, all aiming for continuous healthcare improvement.
Authors: L A D Busweiler; B P L Wijnhoven; M I van Berge Henegouwen; D Henneman; N C T van Grieken; M W J M Wouters; R van Hillegersberg; J W van Sandick Journal: Br J Surg Date: 2016-10-05 Impact factor: 6.939
Authors: Martijn Ten Berge; Naomi Beck; David Jonathan Heineman; Ronald Damhuis; Willem Hans Steup; Pieter Jan van Huijstee; Jan Peter Eerenberg; Eelco Veen; Alexander Maat; Michel Versteegh; Thomas van Brakel; Wilhemina Hendrika Schreurs; Michel Wilhelmus Wouters Journal: Ann Thorac Surg Date: 2018-04-22 Impact factor: 4.330
Authors: David Jonathan Heineman; Martijn Geert Ten Berge; Johannes Marlene Daniels; Michaël Ignatius Versteegh; Perla Jacqueline Marang-van de Mheen; Michael Wilhelmus Wouters; Wilhelmina Hendrika Schreurs Journal: Ann Thorac Surg Date: 2016-09-21 Impact factor: 4.330
Authors: Helen A Powell; Laila J Tata; David R Baldwin; Rosamund A Stanley; Aamir Khakwani; Richard B Hubbard Journal: Thorax Date: 2013-05-17 Impact factor: 9.139
Authors: Christopher W Seder; Michele Salati; Benjamin D Kozower; Cameron D Wright; Pierre-Emmanuel Falcoz; Alessandro Brunelli; Felix G Fernandez Journal: Ann Thorac Surg Date: 2016-03-26 Impact factor: 4.330
Authors: Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609
Authors: Kimberley S Mak; Annelotte C M van Bommel; Caleb Stowell; Janet L Abrahm; Matthew Baker; Clarissa S Baldotto; David R Baldwin; Diana Borthwick; David P Carbone; Aileen B Chen; Jesme Fox; Tom Haswell; Marianna Koczywas; Benjamin D Kozower; Reza J Mehran; Franz M Schramel; Suresh Senan; Robert G Stirling; Jan P van Meerbeeck; Michel W J M Wouters; Michael D Peake Journal: Eur Respir J Date: 2016-07-07 Impact factor: 16.671
Authors: Nansi Maliko; Marcel R Stam; Liesbeth J Boersma; Marie-Jeanne T F D Vrancken Peeters; Michel W J M Wouters; Eline KleinJan; Maurice Mulder; Marion Essers; Coen W Hurkmans; Nina Bijker Journal: Radiat Oncol Date: 2022-04-12 Impact factor: 3.481
Authors: Shantelle Smith; Margaret Brand; Susan Harden; Lisa Briggs; Lillian Leigh; Fraser Brims; Mark Brooke; Vanessa N Brunelli; Collin Chia; Paul Dawkins; Ross Lawrenson; Mary Duffy; Sue Evans; Tracy Leong; Henry Marshall; Dainik Patel; Nick Pavlakis; Jennifer Philip; Nicole Rankin; Nimit Singhal; Emily Stone; Rebecca Tay; Shalini Vinod; Morgan Windsor; Gavin M Wright; David Leong; John Zalcberg; Rob G Stirling Journal: BMJ Open Date: 2022-08-29 Impact factor: 3.006